Mária Fabianová, Martin Javorský, Lucia Klimčáková, Zbynek Schroner, Eva Babjaková, Pavol Pobeha, Ivan Tkáč
Metformin is according to the international guidelines a first line treatment in type 2 diabetes mellitus. The interindividual variability of treatment effect is not negligible and it could be caused by pharmacogenetics and pharmacokinetics affected bygene polymorphism. The most studied topic among the genetic factors is the role of single nucleotide polymorphism (SNP) on the therapeutic effect of metformin. In this paper we focus on a literature review on effects of gene polymorphism, which affect the pharmacokinetics and pharmadynamics of metformin and thus glycaemic compensation. Only a small number of studies were published on this topic and their results are often contradictory. In genes which affect pharmacokinetics of metformin were found associations of SNP SLC22A1, SLC22A2 and SLC47A1 with effect of metformin on glycaemic compensation. In the future the results of pharmacogenetic studies could contribute to a personalized therapy of patients with type 2 diabetes mellitus dependent on their genotype.